ADV 101
Alternative Names: ADV-101; IL-1RAP ADC - AdvesyaLatest Information Update: 23 Jan 2025
Price :
$50 *
At a glance
- Originator Advesya
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 27 Dec 2024 Preclinical trials in Haematological malignancies in France (Parenteral), prior to December 2024 (Advesya pipeline, December 2024)
- 27 Dec 2024 Preclinical trials in Solid tumours in France (Parenteral) prior to December 2024 (Advesya pipeline, December 2024)
- 07 Nov 2024 Pharmacodynamics data from a preclinical study in Esophageal cancer released by Advesya